Abstract 2945: Normalization of Beta Adrenergic Receptor Signaling Improves Left Ventricular Myocyte Function with Urotensin II Receptor Blockade in Murine Heart Failure

Circulation ◽  
2008 ◽  
Vol 118 (suppl_18) ◽  
Author(s):  
Heng-Jie Cheng ◽  
Peng Zhou ◽  
Michael Cross ◽  
Michael F Callahan ◽  
William C Little ◽  
...  

Background. Urotensin II (UII), the most potent vasoconstrictor and its receptors (UT) are upregulated in heart failure (HF). Although the role of UII in cardiac regulation is not fully understood, increasing evidence suggests that in the failing myocardium, UII may exert an enhanced negative modulation on cardiac contractile performance and cardiac β-AR regulation, thus providing a potential mechanism for progressive deterioration in cardiac function in HF. We assessed the hypothesis that blocking UII may prevent HF-induced alterations in cardiac β-adrenergic receptor (AR) expression, restore normal β-adrenergic regulation, and improve left ventricular (LV) myocyte functional performance. Methods. We compared β 1 - and β 3 -AR expression and responses to β- and β 3 -AR stimulation in freshly isolated LV myocytes obtained from 3 groups of mice (6/group): 1) HF-2 months after receiving isoproterenol (ISO, 170 mg/kg, sq, for 2 days); 2) HF/UIIBK-one month after receiving ISO, then urantide, a potent UIIBK (10 −5 M/kg/day via sq implanted osmotic minipump) initiated after the onset of HF and given for 1 month; and 3) Controls. Results. Compared with controls, ISO-treated mice had established HF. Isolated cardiomyocyte studies showed about 42% reductions in cell contraction (dL/dt max , 78 vs 134 μm/s) and relaxation (dR/dt max , 69 vs 120 μm/s) with a much less increase in dL/dt max (29 vs 68%) and dR/dt max (31 vs 62%) in response to superfusion of ISO (10 −8 M). These changes were associated with significantly decreased β 1 -AR mRNA (40%, 0.57 vs 0.95), but increased β 3 -AR mRNA (54%, 0.43 vs 0.28) expression. Treatment with UII BK prevented HF-induced contrast changes of β 1 - and β 3 -AR mRNA expression. The signal ratios of β 1 -AR mRNA (0.85) and β 3 -AR mRNA (0.34) remained close to control levels. Basal and ISO-stimulated adenylate cyclase activity were normal, and ISO-induced increase in dL/dt max (61%) and dR/dt max (58%) were significantly augmented. Conclusion. In a murine model of progressive HF, chronic UIIBK prevents HF-induced contrast alterations of LV β 1 - and β 3 -AR expression, restores normal responsiveness of myocyte to β-AR stimulation, and improves LV myocyte function. Thus, UIIBK may provide a new therapeutic strategy for the treatment of HF.

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Tiankai Li ◽  
Heng-Jie Cheng ◽  
Shadi A Qasem ◽  
Michael Callahan ◽  
Wei-Min Li ◽  
...  

Background: We have shown that Sildenafil (SIL), a selective PDE5 inhibitor reversed left ventricular (LV) dysfunction and β- adrenergic receptors (AR) desensitization in heart failure (HF). However the mechanism is not yet clear. Recent evidence suggests that normal myocardial performance depend on the balance in cardiomyocyte β 3 -, β 1 -, and β 2 -AR. Pivotal restructuring of β-AR system resulting in decline of β-adrenergic reserve plays a crucial role in the development of HF. We assessed the hypothesis that chronic SIL would prevent HF-induced abnormalities of β-AR subtype-stimulated regulation on intrinsic LV myocyte function and [Ca 2+ ] i regulation, thus restoring cardiac function. Methods: Studies were conducted in 3 groups (10/group) of rats: 1) HF, 12 weeks (W) after receiving isoproterenol (ISO) (170 mg/kg sq for 2 days); 2) HF/SIL, 8W after receiving ISO, SIL (70 μg/kg/day sq via mini pump) was initiated and given for 1 M; and 3) controls. After 12W, we compared LV myocyte contractile and [Ca 2+ ] iT responses to β-AR subtype stimulation by random exposure of myocytes to ISO (10 -8 M) or a selective β 1 -, β 2 -, or β 3 -agonist, Norepinephrine (NE, 10 -7 M), Zinterol (ZIN, 10 -5 M) and BRL-37,344 (BRL, 10 -8 M), respectively, during drug superfusion. Results: Only ISO-treated rats had HF showed 46% decreased LV contractility (E ES ) and extensive LV myocardium fibrosis. Compared with normal myocytes (N), in HF myocytes, basal cell contractility (dL/dt max , HF: 77 vs N: 136 μm/s), relaxation and [Ca 2+ ] iT all significantly decreased. ISO-stimulated dL/dt max (31% vs 67%) was attenuated accompanied by a diminished NE-mediated increase in dL/dt max (13% vs 49%), but enhanced BRL-induced decreases in dL/dt max (-29% vs -16%).The response of dL/dt max (25% vs 15%) to ZIN was increased. Importantly, in HF/SIL myocytes, the basal dL/dt max (139 μm/s) and [Ca 2+ ] iT remained close to control values with preserved β-stimulated positive modulation on cell contraction. The increases in dL/dt max in response to ISO (70%) and NE (44%) were similar as in normal myocytes, but repose to ZIN (27%) was enhanced. Conclusions: Chronic SIL reverses β-adrenergic signaling defects, resensitizing the β-AR subtype system modulation on LV myocytes function, thus playing a salutary role in HF.


Circulation ◽  
2015 ◽  
Vol 132 (suppl_3) ◽  
Author(s):  
Tiankai Li ◽  
Xiaowei Zhang ◽  
Heng-Jie Cheng ◽  
Wei-Min Li ◽  
Che Ping Cheng

Background . In heart failure (HF), circulating levels of arginine vasopressin (AVP) are elevated and there is direct relationship between a rise in AVP levels and increased morbidity and mortality. Recent observations further demonstrated the increased AVP 1A receptor (V1AR) expression in failing human hearts and suggested that these alterations may alter cardiac contractile behavior in HF. However, the direct cardiac effects of V1AR in normal and HF remain undetermined. The cellular basis for AVP-associated adverse clinical consequences in HF is unclear. We assessed the hypothesis that in HF, AVP may produce negative modulation on [Ca 2+ ] i regulation and cause direct depression in cardiomyocyte contractile performance. Methods . We assessed LV myocyte functional and calcium transient ([Ca 2+ ] iT ) responses to AVP (10 -7 M) in 8 control and 12 SD rats with isoproterenol (ISO) induced HF (2 months after 170 mg/kg sq for 2 days) in the absence and presence of selective V1AR blockade ([Pmp1, Tyr (OMe) 2, Arg 8 ] AVP, 10 -6 M), or pretreatment of myocytes with G i inhibitor (PTX, 2 μg/ml, 6 hrs). Results . Compared with controls, ISO-treated rats had established HF after ISO at 2 months with significant LV dilatation and decreased ejection fraction (EF, 31% vs 61%). In normal myocytes, versus baselines, AVP superfusion caused no significant changes in myocyte contraction (dL/dt max ) (130.6 vs 136.8 μm/s), relaxation (dR/dt max ) (99.5 vs 103.5 μm/s) and [Ca 2+ ] iT (0.24 vs 0.24). In contrast, in HF, myocyte function was impaired and further depressed by AVP. Versus HF baselines, AVP resulted significantly decreases in dL/dt max (24%, 57.2 vs 75.4 μm/s) and dR/dt max (20%, 39.3 vs 49.0 μm/s) accompanied by reduced [Ca 2+ ] iT (17%, 0.14 vs 0.17). In HF myocytes, these AVP mediated effects were abolished by prior exposure of myocytes to V1AR blockade or PTX. Conclusions . HF alters AVP cardiac effects. In HF, AVP exacerbates the dysfunctional [Ca 2+ ] i homeostasis, producing decreased the peak systolic [Ca 2+ ] iT . AVP causes direct inhibitions of LV myocyte contraction and relaxation, These effects are coupled with the activation of V1AR and are likely to be mediated through the PTX-sensitive G protein pathway and may thus play an important role in promoting functional impairment in HF.


2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
A.J Francis ◽  
J.M Firth ◽  
N Islam ◽  
J Gorelik ◽  
K.T MacLeod

Abstract Background Post-menopausal women have an enhanced risk of developing heart failure, attributed to declining oestrogen levels during menopause. However, the signalling mechanisms remain undetermined. Purpose We aim to determine the role of G-protein coupled oestrogenic receptor 1 (GPER1) in intracellular Ca2+ regulation and the consequences of hormonal changes that may exacerbate the pathophysiology of heart failure. Methods Ovariectomy (OVx) (mimics menopausal hormone changes) or sham surgeries were conducted on female guinea pigs. Left ventricular cardiomyocytes were isolated 150-days post-operatively for experimental use. Cellular t-tubule network and structural integrity was measured using fluorescent di-8-ANEPPs staining and scanning ion conductance microscopy. GPER1 expression and localisation was measured by Western blot and immunostaining. The role of GPER1 activation was measured using selective agonist G-1 in electrophysiological and Ca2+-sensitive dye fluorescence experiments. Results Following oestrogen withdrawal, the t-tubule network density decreased by 13% and z-groove index reduced by 15%. GPER1 predominantly localised to the peri-nuclear endoplasmic reticulum and its expression increased by 32% in OVx. Action potential duration (APD) prolonged in OVx and following GPER1 activation, APD90 shortened by 11% and 25% in sham and OVx respectively. OVx cells had larger peak inward Ca2+ current (ICaL) (by 22%) and sarcoplasmic reticulum (SR) Ca2+ content (by 13%), compared with sham. While GPER1 activation had little effect on peak ICaL or SR content, it reduced Ca2+ transient amplitude (by 20%), SR fractional release (by 11%) in OVx cells. The frequency of occurrence of spontaneous Ca2+ waves evoked by periods of rapid stimulation reduced by 40% and wave-free survival time prolonged in OVx cells following GPER1 activation. Conclusions In the hearts of an animal species whose electrophysiology and intracellular Ca2+ regulation is akin to humans, we show that following oestrogen deficiency, the t-tubule network is down-regulated and becomes disorganised, GPER1 expression is increased and its activation induces negative inotropic responses in cardiomyocytes. This may limit the adverse changes to Ca2+ signalling reported in OVx that could be pro-arrhythmic and exacerbate the progression to heart failure. Funding Acknowledgement Type of funding source: Foundation. Main funding source(s): British Heart Foundation


1999 ◽  
Vol 5 (3) ◽  
pp. 79
Author(s):  
Shintaro Kinugawa ◽  
Hiroyuki Tsutsui ◽  
Tomomi Ide ◽  
Hideo Ustumi ◽  
Nobuhiro Suematsu ◽  
...  

Circulation ◽  
2008 ◽  
Vol 118 (suppl_18) ◽  
Author(s):  
Peng Zhou ◽  
Heng-Jie Cheng ◽  
Michael Cross ◽  
Michael F Callahan ◽  
Bridget Brosnihan ◽  
...  

Voltage-gated Ca 2+ channels play fundamental roles in the regulation of cardiac function by various neurotransmitters. Recently, we have shown that urotensin II (UII), a potent vasoconstrictor, inhibits L-type Ca 2+ current (I Ca,L ) and produces negative inotropic action. In heart failure (HF), the UII-mediated pathway is upregulated, suggesting a therapeutic value of UII receptor antagonist (UII-ANT) for HF. However, the role and mechanism of chronic UII-ANT in HF is unclear. We tested the hypothesis that chronic UII-ANT may improve cardiac I Ca,L , preventing β-adrenergic deregulation on I Ca,L and limit HF progression. We examined plasma levels of norepinephrine (NE), left ventricular (LV) function, and myocyte I Ca,L responses to isoproterenol (ISO) in 3 age-matched groups of mice: HF (n = 7), 2 months after ISO (150 mg/kg sq for 2 days); HF/UII-ANT (n = 11), 1 month after receiving ISO, then urantide, a potent UII-ANT (10 −5 M/kg/day, sq via implanted osmotic mini pump), given for 1 month; and Controls (n = 7). I Ca,L was measured using whole-cell voltage clamp technique. Compared with controls, ISO-treated mice progressed to HF with 4.7-fold increase in plasma NE (18975 vs 4066 pg/ml) and LV dilatation associated with increased myocyte length (ML, 155 vs120 μm) and heart-to-body weight ratio (H/BW, 7.6 vs 5.5 g/kg). Stroke volume (SV, 30.3 vs 61.4 μl) and ejection fraction (EF, 39% vs 60%) were decreased. Compared with normal myocytes, in HF myocytes, I Ca,L was reduced (50%, 3.7 ± 0.2 vs 7.4 ± 0.2 pA/pF), and I Ca,L response to β-AR stimulation (ISO, 10 −8 M) was attenuated (11% vs 35%) (p < 0.01). In HF/UII-ANT mice, plasma NE (5148 pg/ml), SV (57.9 μl), and EF (57%) returned close to control levels with retained normal ML (124 μm) and H/BW (5.9 g/kg). Moreover, compared with controls, in HF/UII-ANT mice, ISO caused similar increases in the peak I Ca,L (32% vs 35%). Chronic UII-ANT treatment normalizes LV L-type Ca 2+ channel basal function and β-adrenergic regulation, leading to regression of LV and myocyte dysfunction and remodeling in mice with ISO-induced HF. This research has received full or partial funding support from the American Heart Association, AHA National Center.


Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Heng-Jie Cheng ◽  
Tiankai Li ◽  
Che Ping Cheng

Background: Sildenafil (SIL), a selective inhibitor of PDE5 has been shown to exert profound beneficial effects in heart failure (HF). Recently we further found that SIL caused regression of cardiac dysfunction in a rat model with isoproterenol (ISO)-induced progressive HF. However, the molecular basis is unclear. We hypothesized that reversal of HF-induced detrimental alterations on the expressions of cardiac SR Ca 2+ -ATPase (SERCA2a), β-adrenergic receptors (AR) and nitric oxide synthase (NOS) isoforms by SIL may play a key role for its salutary role in HF. Methods: Left ventricular (LV) and myocyte function and the protein levels of myocyte β 1 - and β 3 - AR, SERCA2a, phospholamban (PLB) and three NOS were simultaneously evaluated in 3 groups of male rats (6/group): HF , 3 months (M) after receiving ISO (170 mg/kg sq for 2 days); HF/SIL , 2 M after receiving ISO, SIL (70 μg/kg/day sq via mini pump) was initiated and given for 1 M; and Controls (C). Results: Compared with controls, ISO-treated rats progressed to severe HF at 3 M after ISO followed by significantly decreased LV contractility (E ES , HF: 0.7 vs C: 1.2 mmHg/μl) and slowed LV relaxation, reductions in the peak velocity of myocyte shortening (77 vs 136 μm/sec), relengthening (62 vs 104 μm/sec) and [Ca 2+ ] iT (0.15 vs 0.24) accompanied by a diminished myocyte inotropic response to β-AR agonist, ISO (10 -8 M). These abnormalities were associated with concomitant significant decreases in myocyte protein levels of β 1 -AR (0.23 vs 0.64), SERCA2a (0.46 vs 0.80), PLB Ser16 /PLB ratio (0.24 vs 0.40) and eNOS (0.28 vs 0.46), but significantly increases in protein levels of β 3 -AR (0.29 vs 0.10) and iNOS (0.18 vs 0.08) with relatively unchanged nNOS. Chronic SIL prevented the HF-induced decreases in LV and myocyte contraction, relaxation, peak [Ca 2+ ] iT , and restored normal myocyte contractile response to ISO stimulation. With SIL, protein levels of myocyte β 1 - and β 3 -AR, SERCA2a were restored close to control values, but eNOS was significantly elevated than controls (0.77). Conclusions: Chronic SIL prevents HF-caused downregulation of cardiac β 1 -AR and reverse contrast changes between iNOS and β 3 -AR with SERCA 2a and eNOS expression, leading to the preservation of LV and myocyte function, [Ca 2+ ] iT , and β-adrenergic reserve.


2010 ◽  
Vol 54 (5) ◽  
pp. 488-497 ◽  
Author(s):  
Arnaldo Schainberg ◽  
Antônio Ribeiro-Oliveira Jr. ◽  
José Marcio Ribeiro

It has been well documented that there is an increased prevalence of standard cardiovascular (CV) risk factors in association with diabetes and with diabetes-related abnormalities. Hyperglycemia, in particular, also plays an important role. Heart failure (HF) has become a frequent manifestation of cardiovascular disease (CVD) among individuals with diabetes mellitus. Epidemiological studies suggest that the effect of hyperglycemia on HF risk is independent of other known risk factors. Analysis of datasets from populations including individuals with dysglycemia suggests the pathogenic role of hyperglycemia on left ventricular function and on the natural history of HF. Despite substantial epidemiological evidence of the relationship between diabetes and HF, data from available interventional trials assessing the effect of a glucose-lowering strategy on CV outcomes are limited. To provide some insight into these issues, we describe in this review the recent important data to understand the natural course of CV disease in diabetic individuals and the role of hyperglycemia at different times in the progression of HF.


Circulation ◽  
1999 ◽  
Vol 100 (19) ◽  
pp. 2003-2009 ◽  
Author(s):  
Ward V. Houck ◽  
Lydia C. Pan ◽  
Scott B. Kribbs ◽  
Mark J. Clair ◽  
George M. McDaniel ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document